Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea

Table 2 Baseline IBSSI-J score

		N	Mean ± SD	Min	Max	Median	First-quartile points	Third-quartile points	t-test
Overall score	Placebo	50	246.6 ± 80.52	80	410	245	200	290	t = −1.123, df = 95, P = 0.264
Overall score	Ramosetron 5 μg	47	267.1 ± 98.75	60	440	275	180	355	t = −1.123, df = 95, P = 0.264
Severity of abdominal pain	Placebo	50	44.3 ± 26.71	0	100	47.5	20	70	t = −0.647, df = 95, P = 0.519
Severity of abdominal pain	Ramosetron 5 μg	47	47.8 ± 26.70	0	90	50	30	70	t = −0.647, df = 95, P = 0.519
Frequency of abdominal pain	Placebo	50	57.4 ± 33.61	0	100	60	30	90	t = 0.335, df = 95, P = 0.739
Frequency of abdominal pain	Ramosetron 5 μg	47	55.1 ± 33.87	0	100	60	30	90	t = 0.335, df = 95, P = 0.739
Intensity of abdominal distention	Placebo	50	23.8 ± 25.65	0	80	17.5	0	50	t = −2.007, df = 95, P = 0.048
Intensity of abdominal distention	Ramosetron 5 μg	47	35.6 ± 32.25	0	100	30	0	60	t = −2.007, df = 95, P = 0.048
Dissatisfaction with bowel habits	Placebo	50	66.8 ± 22.78	20	100	60	50	90	t = −0.361, df = 95, P = 0.719
Dissatisfaction with bowel habits	Ramosetron 5 μg	47	68.6 ± 25.55	0	100	70	50	90	t = −0.361, df = 95, P = 0.719
Interference with QOL	Placebo	50	54.3 ± 27.39	0	100	55	30	80	t = −1.013, df = 95, P = 0.314
Interference with QOL	Ramosetron 5 μg	47	60.0 ± 27.59	0	100	60	40	80	t = −1.013, df = 95, P = 0.314

Data are expressed as mean ± standard deviation. P values were calculated using analysis of variance

ISSN: 1751-0759